CELL INTELLIGENCE · 肿瘤细胞治疗研究

多发性骨髓瘤中 T 细胞重定向治疗的皮肤毒性：EADV 工作组立场文件与实践建议

Cutaneous Toxicities of T-Cell-Redirecting Therapies in Multiple Myeloma: An EADV Task Force Position Paper and Practical Recommendations.

优化 BCMA 靶向 T 细胞衔接疗法在三类暴露的复发/难治性多发性骨髓瘤患者中的真实世界应用：意大利改良德尔菲共识

Optimizing the Real-World Use of BCMA-Targeted T-Cell-Engaging Therapies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: A

在本文中，我们探讨了抗 BCMA BsAb 在 TCE RRMM 患者中真实世界应用相关的主要挑战，并提供专家建议，以补充现有指南并支持临床实践。

复发/难治性多发性骨髓瘤中双特异性抗体与 CAR-T 细胞治疗的真实世界分析：全球 TriNetX 发现与当代验证队列

Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemp

疾病生物学与桥接策略对复发/难治性多发性骨髓瘤 CAR-T 细胞治疗后结局的影响

Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma.

多发性骨髓瘤免疫治疗序贯的真实世界证据：既往 GPRC5D 靶向治疗后 BCMA 靶向双特异性抗体可带来持久缓解

Real-World Evidence of Immunotherapy Sequencing in Multiple Myeloma: Durable Responses With BCMA-Targeting Bispecific Antibodies Following Prior GPRC5

靶向 BCMA 的双特异性抗体为经靶向 GPRC5D 的双特异性抗体治疗后进展的患者提供了一种有效且耐受性良好的治疗选择，支持该序贯方案作为一种有前景策略的可行性。

从 CAR-T 到 CAAR-T：通过独特型导向细胞治疗重新定义 B 细胞恶性肿瘤的靶向策略

From CAR-T to CAAR-T: redefining targeting strategies in B-cell malignancies through idiotype-directed cellular therapy.

CAR-T 细胞治疗后的免疫效应细胞相关噬血细胞性淋巴组织细胞增生症：一项真实世界研究结果

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy: Results of a Real-World Study.

四重暴露/难治性多发性骨髓瘤：既往接受过抗 CD38、IMiDs、蛋白酶体抑制剂与 BCMA 靶向治疗的患者

Quad-Exposed/Refractory Multiple Myeloma: Patients Previously Treated With Anti-CD38, IMiDs, Proteasome Inhibitors, and BCMA-Targeted Therapies.

接受 ciltacabtagene autoleucel 治疗的复发/难治性多发性骨髓瘤患者中的非 ICANS 神经系统事件：CARTITUDE 研究中的临床表现与管理

Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Ma

Teclistamab 对抗 BCMA CAR-T 流式检测的干扰：持续时间及临床意义

Teclistamab interference with anti-BCMA chimeric antigen receptor T-cell detection by flow cytometry: duration and clinical implications.